Longitudinal Assessment of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019. (4th March 2021)

• Record Type: Journal Article
• Authors: Noh, Ji Yun; Kwak, Jeong-Eun; Yang, Jeong-Sun; Hwang, Soon Young; Yoon, Jin Gu; Seong, Hye; Hyun, Hakjun; Lim, Chae Seung; Yoon, Soo-Young; Ryou, Jungsang; Lee, Joo-Yeon; Kim, Sung-Soon; Park, Su-Hyung; Cheong, Hee Jin; Kim, Woo Joo; Shin, Eui-Cheol; Song, Joon Young
• Is Part Of: Journal of infectious diseases. Volume 224:Supplement 5(2021)
• Page Start: 754
• Page End: 763
• Publication Date: 2021-03-04
• Subjects: cellular immunity -- COVID-19 -- humoral immunity -- longevity -- SARS-CoV-2; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiab124
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Background: There is insufficient data on the longevity of immunity acquired after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods: We aimed to evaluate the duration of SARS-CoV-2-specific humoral and cellular immunity according to the clinical severity of coronavirus disease 2019 (COVID-19). The study population comprised asymptomatic (n = 14), symptomatic/nonpneumonic (n = 42), and pneumonic (n = 41) patients. Results: The anti-SARS-CoV-2 immunoglobulin class G and neutralizing antibody (NAb) titers lasted until 6 months after diagnosis, with positivity rates of 66.7% and 86.9%, respectively. Older age, prolonged viral shedding, and accompanying pneumonia were more frequently found in patients with sustained humoral immunity. Severe acute respiratory syndrome coronavirus 2-specific T-cell response was strongly observed in pneumonic patients and prominent in individuals with sustained humoral immunity. Conclusions: In conclusion, most (>85%) patients carry NAb until 6 months after diagnosis of SARS-CoV-2 infection, providing insights for establishing vaccination strategies against COVID-19. Abstract : Anti-SARS-CoV-2-neutralizing antibodies persisted in more than 85% of patients with COVID-19 until 6 months after diagnosis. Older age, prolonged viral shedding, and accompanying pneumonia were strongly associated with sustained antibody response in patients with COVID-19.